Matinas BioPharma Holdings, Inc. has terminated its agreement with a former financial advisor, which previously entitled the advisor to up to $4.0 million in cash and stock for business combinations. In connection with the termination, the company paid the advisor $562,500 in cash and exchanged mutual releases. This action removes potential future success-fee obligations related to strategic transactions.
Matinas BioPharma implemented a one-for-fifteen (1:15) reverse stock split of its common stock effective September 28, 2026. The split was previously approved by stockholders at the 2025 annual meeting and is intended to adjust the share price for continued trading on the NYSE American.
Matinas BioPharma announced that its Board of Directors has approved a 1-for-15 reverse stock split of its common stock, effective September 28, 2026. The split is intended to help the company maintain its listing on the NYSE American exchange by increasing the per-share trading price. No fractional shares will be issued, and stockholders will instead receive proportional cash payments.